Literature DB >> 24984530

The ideal cervical cancer screening recommendation for Belgium, an industrialized country in Europe.

W A A Tjalma.   

Abstract

Cervical cancer should be a historical disease, why are we not succeeding! The prophylactic vaccination will reduce cervical cancer by almost 80% in Belgium. Cervical cancer screening should therefore remain in order to prevent the remaining 20%. The current used Pap cytology test misses 50% of all clinically significant precancers and cancers at the time of testing. The test should remain but the analysis should be altered. The screening should be modified based on our knowledge of human papillomavirus (HPV) as causal factor. Instead of looking for a cell abnormality, one should look for the presence of HPV. Then depending on the test, only two to ten percent of all relevant lesions are missed. The introduction of the vaccination should lead to the re-introduction of the screening based on HPV. This will not only lead to a considerable reduction in morbidity and mortality, allow longer screening intervals, but it will also be more cost-effective. More for less should be the driving force in cervical cancer screening if we want to be successful.

Entities:  

Mesh:

Year:  2014        PMID: 24984530

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium.

Authors:  W A A Tjalma; X B Trinh; M Rosenlund; A P Makar; F Kridelka; D Rosillon; P A Van Dam; S Collas De Souza; K Holl; P Simon; D Jenkins
Journal:  Facts Views Vis Obgyn       Date:  2015

2.  Methylation pattern of CDH1 promoter and its association with CDH1 gene expression in cytological cervical specimens.

Authors:  Veronika Holubeková; Andrea Mendelová; Marián Grendár; Sandra Meršaková; Ivana Kapustová; Karin Jašek; Andrea Vaňochová; Jan Danko; Zora Lasabová
Journal:  Oncol Lett       Date:  2016-08-12       Impact factor: 2.967

Review 3.  Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer.

Authors:  Xaveer Van Ostade; Martin Dom; Wiebren Tjalma; Geert Van Raemdonck
Journal:  Arch Gynecol Obstet       Date:  2017-11-15       Impact factor: 2.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.